Full-Time

Associate Business Consultant

Life Sciences Commercial

Updated on 8/24/2026

Veeva Systems

Veeva Systems

10,001+ employees

Cloud-based quality, regulatory, and claims management

Compensation Overview

$85k/yr

No H1B Sponsorship

New York, NY, USA

Hybrid

Typically requires two to three days in the office per week; candidates must live within a 45-minute to one-hour commute of the New York City or Boston office.

Bachelor's

Category
Consulting (1)
Required Skills
Data Analysis

Get referred to Veeva Systems

See people who can refer or advise you

Requirements
  • A bachelor's degree in any major with a GPA between 3.0 and 4.0 is required.
  • Candidates must be recent university graduates with no more than one year of postgraduate experience.
  • Candidates must be legally authorized to work in the United States.
  • Candidates must be willing to travel up to 20% of their time per year.
  • Candidates must demonstrate strong verbal and written communication skills.
  • Candidates must be process-driven and comfortable working with operations, numbers, and other data to identify improvement opportunities.
Responsibilities
  • Support and deliver all components of customer engagements, including customer communications, workshops, stakeholder interviews, process and data analysis, and timeline management.
  • Collaborate with Business Consultants to create deliverables that optimize customer operating and engagement models, processes, and business performance.
  • Leverage Veeva software and data to develop tangible business and operational solutions.

Veeva Systems provides cloud-based software that helps consumer goods and chemical companies manage quality, regulatory compliance, and advertising claims. The platform works by connecting different departments—from the supply chain to marketing—to provide a single source of data that tracks a product's journey and ensures it meets safety standards. Unlike competitors that offer general business tools, Veeva specializes in navigating the highly complex regulations originally found in the life sciences sector and applies that specific expertise to other regulated industries. The company's goal is to help businesses bring safe, sustainable, and compliant products to market faster by providing end-to-end visibility and traceability.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pleasanton, California

Founded

2007

Get referred to Veeva Systems

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal Q1 2027 revenue reached $882.9 million, up 16% year over year.
  • Veeva AI reached all customers in August 2026, expanding monetizable workflow automation.
  • Copli integration and EHS launch create cross-sell momentum across quality, safety, and MLR.

What critics are saying

  • Salesforce and internal pharma tech teams target Veeva’s CRM moat during 2026 migrations.
  • Falcon MLR must prove productivity gains before 2027, or agentic AI becomes marketing theater.
  • A failed Lilly rollout would damage Veeva’s flagship credibility and slow enterprise standardization.

What makes Veeva Systems unique

  • Veeva owns regulated life-sciences workflows from R&D through commercial, not generic CRM.
  • Eli Lilly committed globally to Veeva Vault CRM on August 11, 2026.
  • Falcon MLR and Veeva EHS deepen switching costs across compliance-critical workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Parental leave

PTO

Free food

Health, dental, & vision insurance

Gym membership reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 22nd, 2026
Eli Lilly adopts Veeva Vault CRM globally as Veeva eyes $4.7B revenue by 2029

Veeva Systems has secured a global deployment commitment for Vault CRM from Eli Lilly. The company also announced that President and Chief Customer Officer Thomas D. Schwenger will depart in October 2026, with Dan Rizzo succeeding him as EVP of Sales, Consulting, and Services. Wall Street analysts expect higher quarterly earnings and revenue for Veeva. The Eli Lilly deployment reinforces the trend of top pharmaceutical companies consolidating commercial workflows on Veeva's platform. Analysts project Veeva will reach $4.5 billion in revenue and $1.3 billion in earnings by 2029, requiring 12.7% annual revenue growth. However, investors should note the company's concentrated exposure to major CRM customers. AI agents in safety and clinical workflows remain a potential factor that could affect both forecasts and investor confidence.

Express-Press-Release.net
Aug 22nd, 2026
Healthcare data technology market: Challenges in privacy and compliance.

Healthcare data technology market: Challenges in privacy and compliance. Healthcare organizations are sitting on more data than ever before - electronic health records, connected devices, claims, imaging, and real-world evidence - and the race is on to turn that raw information into something usable. That race is fueling rapid growth in the healthcare data technology market, a space built around integrating, standardizing, securing, and monetizing health data at scale. Here's a closer look at where the market stands today, what's driving it forward, and the roadblocks still standing in the way. Key Market Facts The global healthcare data technology market was valued at USD 3.1 billion in 2024 and is projected to grow from USD 4.0 billion in 2026 to USD 9.5 billion by 2033, expanding at a compound annual growth rate of 13.4% between 2025 and 2033. A few other numbers worth noting: * North America led the market in 2024, capturing a 46.5% revenue share, while Asia Pacific is on track to be the fastest-growing region going forward. * By technology, the health data integration and monetization segment dominated in 2024, holding more than 66.55% of total revenue, as providers work to unify EHRs, clinical trial data, and real-world evidence into single, usable pipelines. * The data harmonization and structuring segment, though smaller today, is expected to post the fastest growth rate of any segment over the forecast period, largely thanks to AI and NLP tools that can standardize messy, unstructured clinical data. * EHR adoption remains the backbone of this demand: as of December 2024, roughly 88% of U.S. office-based physicians were using an EMR/EHR system, with nearly 78% on a certified platform - a base that keeps generating more data to integrate and analyze. * The competitive landscape is notably fragmented, with dozens of established and emerging vendors - including IQVIA, Veeva Systems, Oracle (Cerner), Optum, Datavant, TriNetX, and Flatiron Health - all competing for share, which keeps innovation and partnership activity high. Major Industry Trends AI and advanced analytics are moving from pilot to production. Vendors are embedding generative AI and machine learning directly into data platforms rather than treating them as add-ons. Oracle's newly launched AI Data Platform, for example, is designed to help enterprises build AI-ready data lakes and deploy AI-driven applications directly on top of unified data. Global harmonization initiatives are reshaping the data landscape. Governments and health systems are investing heavily in standardizing and connecting fragmented health records. Europe's Health Data Space regulation, formally adopted in 2025, sets a legally binding framework for cross-border health data access across the EU, covering both direct patient care and secondary research use. The UK has committed roughly £600 million toward a national Health Data Research Service, while Germany has launched a similarly ambitious medical informatics funding program - all aimed at making health data more accessible for research and care. Discover more Internet & Telecom Commercial Distribution Public Relations Interoperability is becoming a regulatory mandate, not just a best practice. In the U.S., federal regulators have intensified enforcement of information-blocking rules under the 21st Century Cures Act, pushing providers and vendors to make electronic health information more freely accessible and exchangeable. Strategic partnerships and M&A are accelerating capability-building. Rather than building every capability in-house, companies are teaming up or acquiring their way into new strengths - from IQVIA and Veeva's long-term global partnership to streamline clinical trials, to Samsung's acquisition of digital health platform Xealth, to Commvault's move to acquire data security firm Satori Cyber to strengthen protections around AI training data. Social determinants of health (SDOH) and real-world data are being folded into core platforms. Partnerships like HealthEdge and Unite Us embedding SDOH data into care management platforms reflect a broader shift toward more holistic, value-based data models that go beyond clinical records alone. Emerging technologies are tackling harmonization at scale. Graph databases, federated learning frameworks, and AI-driven semantic mapping are increasingly used to link genomic, clinical, and multi-institutional datasets - enabling collaborative research without centralizing sensitive patient data. Need data specific to your market or segment? This report can be tailored with additional countries, segments, or data points to match your exact research needs - with free customization available on purchase. Request Report Customization Primary System Challenges Data fragmentation across legacy systems. Many healthcare organizations still operate with claims, patient records, and lab results scattered across disconnected legacy systems, creating operational bottlenecks and slowing down everything from claims processing to clinical research. Regulatory complexity and compliance costs. Stringent privacy and security frameworks - HIPAA, GDPR, and a growing patchwork of regional health data governance rules - demand robust compliance and audit capabilities. While these regulations push innovation in secure data management, they also add real implementation complexity and cost for both providers and vendors. Discover more Communications & Media Studies communication Interoperability gaps between platforms. Despite widespread EHR adoption, getting different systems to talk to each other in a standardized way (HL7/FHIR and beyond) remains a persistent hurdle, particularly for organizations trying to merge imaging, genomic, and unstructured clinical data. Balancing data monetization with privacy. As organizations look to unlock value from health data - through analytics, research partnerships, or licensing - they must simultaneously protect patient privacy, driving demand for de-identification, pseudonymization, and governance tools that can slow down time-to-insight. Scalability under growing data volumes. As data volume and variety expand (from wearables, genomics, and real-world evidence), organizations need cloud-native, auto-scaling infrastructure - a shift that isn't trivial for institutions still running on manual or semi-automated processes. Regional disparities in infrastructure and investment. While North America and Europe are pushing ahead with major national data initiatives, regions like Latin America and parts of MEA are still working to modernize foundational health data infrastructure, creating uneven adoption rates globally. The bigger picture: healthcare data technology is no longer a back-office IT concern - it's becoming central to how care gets delivered, how research gets funded, and how health systems compete. Organizations that solve for interoperability, compliance, and scalability today will be the ones best positioned to capture value as the market roughly triples in size by 2033. Discover more communications Business & Industrial Want the Full Picture? See who's leading the market. Get access to detailed profiles of the key players shaping the healthcare data technology space - including IQVIA, Veeva Systems, Oracle, Optum, Datavant, and more - along with their strategies, partnerships, and market positioning. Explore Key Players Explore our dedicated business services: * U.S. Healthcare Facility Mapping & Intelligence Portal - Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities - including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs. * Brainshare Consulting - End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics. * Custom Research - Get a market intelligence report tailored to your specific requirements and aligned with your business goals. * Consumer Insights - Capture real, evolving consumer sentiment and behavior to help you make data driven strategies. * Horizon Databooks - Access the world's largest portal of Market Reports & Statistics * Investment Insights - Make investment decisions with data driven insights, powered by domain and technology * Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage. About us: Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide. Matched content.

PR Newswire
Aug 11th, 2026
Veeva Vault CRM selected by Eli Lilly and Company.

Veeva Vault CRM selected by Eli Lilly and Company. Aug 11, 2026, 07:03 ET PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ - Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has selected Veeva Vault CRM globally. Vault CRM is part of the Vault CRM application suite, which forms the technological foundation for "Agentic Commercial" - the new sales model that uses AI to help more patients get the right medications. "We are very excited to expand our strategic collaboration with Veeva by transitioning to Vault CRM," said Giuseppe Firenze, Senior Vice President of U.S. HCP and Field Engagement Hub at Lilly. "Vault CRM will help Lilly make our breakthrough medications accessible to more patients." "Lilly develops medicines that improve the lives of people around the world," said Peter Gassner, CEO of Veeva. "We are proud to expand our strategic collaboration with Lilly as part of the global rollout of Vault CRM." Learn more about the Veeva Vault CRM suite, including the Agentic Call Report for generating commercial evidence, at veeva.com/crm. About Veeva Systems Veeva provides the industry cloud for life sciences with applications, agents, data, and consulting. Veeva is committed to innovation, product quality, and customer success, serving more than 1,500 customers, from the world's largest pharmaceutical companies to emerging biotech companies. As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com. Forward-looking statements of Veeva This press release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from the use of our products and services. These statements are based on our current expectations. Actual results may differ materially from those described in this press release, and we undertake no obligation to update such statements. There are numerous risks that could potentially negatively affect our results, including the risks and uncertainties disclosed in our Form 10-Q for the fiscal quarter ended April 30, 2026 - available here (see pages 33 and 34 for a summary of risks that could affect our business) - as well as in our subsequent SEC filings, which you can access at sec.gov. Contact: Maria Scurry Veeva Systems [email protected] Meera Lakhani-Patel Veeva Systems, Europe [email protected]

Yahoo Finance
Jul 30th, 2026
Vulcan Value Partners buys Veeva Systems as life sciences software firm grows revenue 16%, EBIT 24%

Vulcan Value Partners added Veeva Systems to its All-Cap strategy in Q2 2026, describing the company as the dominant vertical market software system of record for the life sciences industry. The investment firm noted that Veeva's customers rely on its platform to run their entire business, from drug development and regulatory approval to manufacturing, selling, and marketing. Veeva grew revenue and EBIT by 16% and 24% respectively in 2025 and maintained strong momentum into 2026. Despite these results, the stock fell nearly 20% year-to-date through end-June, moving in sympathy with the broader application software sector. On 29 July 2026, Veeva shares closed at $207.91, giving it a market capitalisation of $33.77 billion. According to data, 62 hedge funds held Veeva at the end of Q1, down from 75 in the previous quarter.

IDDI
Jul 17th, 2026
IDDI joins Veeva CRO Partner Program to expand eClinical technology offerings for clinical trials.

IDDI joins Veeva CRO Partner Program to expand eClinical technology offerings for clinical trials. July 17, 2026. BRUSSELS; RALEIGH, N.C.; July. 16, 2026 - IDDI today announced it has joined the Veeva CRO Partner Program, further expanding its eClinical technology ecosystem to support sponsors running clinical trials of all sizes and complexities. As a leading provider of biometrics services, including biostatistics, data management, RTSM, and strategic consulting, IDDI is committed to helping sponsors select the technologies that best fit their protocol requirements and operational needs. Through this partnership, IDDI will expand the range of eClinical solutions available to its customers by adding Veeva Clinical Data applications, including Veeva EDC, Veeva DQS, Veeva eCOA, and Veeva RTSM. By combining scientific expertise with advanced technology solutions, IDDI helps sponsors build efficient, scalable clinical trial strategies that support high-quality data collection, streamlined study execution, and successful clinical outcomes. "Sponsors need the flexibility to build clinical technology ecosystems that support their unique study requirements," said Tara Kervin, Chief Operating Officer at IDDI. "By joining the Veeva CRO Partner Program, we are expanding our eClinical technology portfolio with Veeva's EDC, DQS, eCOA, and RTSM solutions. Together, we can better align technology with protocol design, giving sponsors greater choice while helping them execute studies more efficiently and confidently." The partnership reflects a shared commitment to providing life sciences organizations with modern, connected solutions that support efficient trial execution and enable teams to manage increasingly complex studies with confidence. About IDDI IDDI is a trusted clinical data science partner. With 35+ years of research-driven experience, IDDI Inc. combine therapeutic expertise, biostatistical leadership, and regulatory insight to mitigate risk from design to registration and beyond. IDDI Inc. deliver uncompromising excellence in biostatistics, strategic consulting, clinical data management, IDMCs, and supporting eClinical technologies, because when every data point represents a patient, perfection is the only option.